title: Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
authors.affiliation: Departments of Leukemia and Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
authors.forename: S
authors.initials: S
authors.lastname: Faderl
authors.forename: M
authors.initials: M
authors.lastname: Talpaz
authors.forename: H M
authors.initials: HM
authors.lastname: Kantarjian
authors.forename: Z
authors.initials: Z
authors.lastname: Estrov
mesh_terms: D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction / Q000379:methods*
chemical_list: D016044:Fusion Proteins, bcr-abl